Brief: HDL Therapeutics Plans To Become Publicly Traded Via Business Combination With $225 Mln Swiftmerge

Aleanna

24/04/2023 18:36

April 24 (Reuters) - Swiftmerge Acquisition Corp
 IVCP.O :
    * HDL THERAPEUTICS INC PLANS TO BECOME PUBLICLY TRADED VIA A
BUSINESS COMBINATION WITH $225 MILLION SWIFTMERGE (NASDAQ: IVCP)
WITH GOAL TO TRANSFORM CARDIOVASCULAR DISEASE TREATMENT
    * SWIFTMERGE ACQUISITION CORP - UNDER TERMS OF LOI,
SWIFTMERGE AND
HDL THERAPEUTICS WOULD BECOME A COMBINED ENTITY
    * SWIFTMERGE ACQUISITION CORP- UNDER DEAL HDL THERAPEUTICS'
EXISTING EQUITY HOLDERS WILL ROLL 100% OF THEIR EQUITY INTO
COMBINED PUBLIC COMPANY
    * SWIFTMERGE ACQUISITION CORP - SIGNING OF A NON-BINDING
LETTER OF
INTENT FOR A BUSINESS COMBINATION WITH HDL THERAPEUTICS INC

Source text for Eikon:  ID:nBw8tpBFka 
Further company coverage:  IVCP.O 

 ((Reuters.Briefs@thomsonreuters.com;))